Does Finasteride Cause High-Grade Prostate Cancer?

Finasteride does not appear to cause high-grade prostate cancer. A landmark trial in 2003 raised that alarm after finding more aggressive-looking tumors in men taking the drug, but nearly two decades of follow-up analysis has traced most of that signal to detection artifacts rather than genuine tumor promotion. Men who took finasteride for seven years did not die sooner or have worse prostate cancer outcomes than men who took a placebo, even after 18 years of tracking. The story behind those dueling findings is worth understanding, especially if you take finasteride for hair loss or an enlarged prostate and your doctor has mentioned the black-box warning on the label.

The Trial That Sparked the Controversy

The Prostate Cancer Prevention Trial (PCPT) randomized nearly 19,000 men aged 55 and older to either 5 mg of finasteride daily or a placebo for seven years. The headline result was encouraging: prostate cancer was detected in about 18.4 percent of the finasteride group compared with 24.4 percent in the placebo group, a roughly 25 percent reduction in overall prevalence.¹ But buried in that good news was a troubling detail: tumors graded Gleason 7 or higher (the ones considered more aggressive) turned up in about 6.4 percent of men on finasteride versus 5.1 percent of men on placebo.¹

That finding dominated the conversation. The FDA eventually added a black-box warning to finasteride’s label citing the potential risk of high-grade prostate cancer.² Many clinicians backed away from prescribing finasteride for cancer prevention, and men already on the drug grew anxious. But almost immediately, researchers began asking whether the increase in high-grade cancers was real or whether something about finasteride was making the test better at finding cancers that were already there.

How a Smaller Prostate Changes What Biopsies Find

Finasteride shrinks the prostate gland by roughly 25 percent.² That sounds like a side note, but it has a direct effect on what a biopsy needle finds. When the same number of needle cores are taken from a smaller gland, each core samples a larger fraction of the total tissue. Any cancer present, including aggressive cancer, is more likely to be hit by a needle in a smaller organ than in a larger one. Researchers call this detection bias, and it is the single most studied explanation for the PCPT’s high-grade result.

A modeling analysis of the PCPT data tested this hypothesis directly. In the placebo group, the likelihood of detecting high-grade cancer dropped as prostate volume increased; for every 10 cubic centimeter increase in prostate size, the odds of finding high-grade cancer fell by about 19 percent. When the researchers applied that same volume-detection relationship to the finasteride group and adjusted for gland volume and the number of biopsy cores, the apparent excess of high-grade cancer effectively vanished. The odds ratio for high-grade cancer in finasteride users dropped from a statistically significant 1.27 to a non-significant 1.03 in one model and from 1.14 to 0.88 in another.³ A separate bias-adjusted analysis of the same trial concluded outright that finasteride does not increase the risk of high-grade prostate cancer once the detection advantage is accounted for.⁴

Grading Artifacts Under the Microscope

Detection bias was not the only confounder. Finasteride, like all forms of androgen-deprivation therapy, physically changes the way prostate cells look under a microscope. The drug induces cytoplasmic clearing, nuclear and nucleolar shrinkage, and chromatin condensation in both benign and cancerous prostate tissue.⁵ These changes make the cellular architecture of a tumor appear more disorganized at a glance, which is the same feature pathologists use to assign higher Gleason grades. In other words, a tumor that would score as Gleason 6 in an untreated prostate could score as Gleason 7 in a finasteride-treated prostate, not because it behaves more aggressively, but because the drug altered its cosmetic appearance. Research on treated cancers found significantly higher architectural Gleason grades despite lower nuclear grades and smaller nucleolar diameters, a mismatch that points toward grading artifact rather than genuine biological aggressiveness.⁵

Put simply, finasteride may have been making some cancers look scarier on paper without actually making them scarier in the body. Combined with the detection bias from smaller prostates, these two artifacts together offer a compelling explanation for nearly all of the high-grade excess the PCPT originally reported.

Eighteen Years of Follow-Up Settled the Survival Question

If finasteride genuinely caused more aggressive cancers, men who took it should eventually die at higher rates. They did not. Researchers followed PCPT participants for a median of 18 years and found no meaningful difference in overall survival. Fifteen-year survival rates were 78.0 percent in the finasteride group and 78.2 percent in the placebo group. The hazard ratio for death with finasteride was 1.02, statistically indistinguishable from 1.0.⁶

Even when looking specifically at men diagnosed with high-grade prostate cancer, ten-year survival rates were essentially identical: 73.0 percent in the finasteride group and 73.6 percent in the placebo group.⁶ If finasteride had promoted genuinely lethal tumors, those numbers would have diverged. They did not. The researchers concluded that while high-grade cancer was more commonly detected in the finasteride group, there was no significant difference in overall survival or in survival after a prostate cancer diagnosis between the groups.

What Population-Level Data Shows

The PCPT was a controlled trial with specific enrollment criteria. Real-world evidence from population registries has since added a broader picture. A large study published in JAMA Oncology examined men who used 5-alpha-reductase inhibitors (the drug class that includes finasteride) and found that longer exposure was associated with lower prostate cancer mortality. Men who used these drugs for more than eight years had a prostate cancer mortality hazard ratio of 0.44 compared with non-users, meaning their risk of dying from prostate cancer was less than half. No significant difference was seen in all-cause mortality between users and non-users.⁷

A Finnish population-based study found a similar pattern: finasteride use was linked to a roughly 41 percent lower incidence of low-grade tumors, with the protective effect growing stronger the longer men took the drug. The rate of high-grade tumors was statistically unchanged.⁸ That finding aligns with what the PCPT showed once biases were accounted for: finasteride prevents low-grade cancers without promoting high-grade ones.

The Dutasteride Story

Dutasteride, a related 5-alpha-reductase inhibitor that blocks both enzyme subtypes rather than just one, went through its own large prevention trial called REDUCE. Among the roughly 6,700 men who underwent biopsy, dutasteride reduced overall prostate cancer detection by about 23 percent over four years compared with placebo.⁹ Like the PCPT, REDUCE initially showed a slight uptick in high-grade cancers, though the pattern and explanations mirrored those already described for finasteride. The consistency across two different drugs, two separate trials, and overlapping bias analyses strengthens the conclusion that the apparent high-grade signal is a class-wide detection artifact rather than evidence that these drugs promote aggressive disease.

What This Means for PSA Screening

If you take finasteride, your PSA levels will drop, and that has practical consequences for cancer screening. A PSA of 4.0 ng/mL has traditionally been the threshold that triggers a biopsy recommendation. Finasteride suppresses PSA, so a reading that looks reassuringly low might actually be hiding a cancer that would have been flagged in a man not taking the drug.

The standard clinical adjustment has been to double the measured PSA value in men on finasteride, but the evidence suggests this “doubling rule” is an oversimplification. In the PCPT cohort, the adjustment factor needed to preserve the true median PSA increased from about 2.0 at two years to 2.5 after seven years on finasteride.¹⁰ A separate review found that simple doubling may overestimate true PSA in the first six to nine months of treatment, work reasonably well between one and three years, and underestimate it beyond three years.¹¹ The takeaway is straightforward: if you are on finasteride, make sure your doctor knows. PSA values need context-dependent interpretation that accounts for how long you have been on the drug.

There is also an upside to this dynamic. Finasteride appears to improve the sensitivity of the PSA test, meaning that when PSA does rise in a man taking finasteride, it is a more reliable signal of underlying cancer than the same rise in an untreated man.² With proper PSA adjustment, finasteride may actually sharpen screening accuracy rather than undermine it.

The Hair Loss Dose and Prostate Cancer Risk

Most of the evidence discussed so far comes from trials using 5 mg of finasteride daily, the dose prescribed for benign prostatic hyperplasia. Millions of men take finasteride at 1 mg per day for hair loss, so the obvious question is whether the same concerns apply.

A randomized trial of 1 mg finasteride in men aged 40 to 60 with androgenetic alopecia found that even the lower dose reduced serum PSA by about 40 percent in men aged 40 to 49 and about 50 percent in men aged 50 to 60 over 48 weeks.¹² Those are substantial drops, confirming that the biological effects relevant to prostate cancer detection are not limited to the higher dose. The researchers concluded that the same PSA adjustment recommendations used for the 5 mg dose should also apply to the 1 mg preparation.

No large prevention trial has studied the 1 mg dose specifically for prostate cancer outcomes, so whether it provides the same roughly 25 percent reduction in overall cancer risk is unknown. But the PSA suppression data makes clear that men taking low-dose finasteride for hair loss need to be just as vigilant about telling their doctors, particularly when PSA screening is being discussed. A PSA result that appears normal in a man on 1 mg finasteride may not actually be normal.

Finasteride in Active Surveillance

For men already diagnosed with low-risk prostate cancer, active surveillance (monitoring the cancer instead of treating it immediately) is a standard approach. The question of whether finasteride could help keep these tumors from progressing is an active area of research. A systematic review and meta-analysis of nonsurgical interventions for men on active surveillance found that 5-alpha-reductase inhibitors were associated with significantly improved progression-free survival, with a hazard ratio of 0.59 and no increased toxicity signals.¹³

A randomized phase 3 trial called FINESSE is now underway to test this more rigorously. The study aims to enroll 550 men with low to intermediate-risk prostate cancer on active surveillance, randomizing them to finasteride or placebo. Researchers estimate that finasteride could reduce the rate of patients leaving active surveillance (due to disease progression or treatment) by about 50 percent over four years.¹⁴ If those results pan out, finasteride could shift from being viewed primarily as a cancer prevention drug to also serving as a tool that helps men with existing low-risk cancer avoid or delay surgery and radiation.

Why the FDA Warning Still Exists

Given the weight of evidence against a genuine increase in aggressive cancers, it is reasonable to wonder why finasteride’s label still carries a black-box warning. The short answer is that FDA label changes reflect a regulatory process, not a living scientific consensus. The warning was added based on the raw PCPT data before the detection-bias analyses were complete. Removing or revising an existing black-box warning requires a formal review cycle, and pharmaceutical manufacturers have had limited commercial incentive to pursue one for a drug that has long been available as a cheap generic.

Professional medical organizations have taken a somewhat more nuanced position. The American Society of Clinical Oncology and the American Urological Association jointly recommended in 2008 that men with a PSA of 3.0 ng/mL or below who are regularly screened may benefit from discussing finasteride for prostate cancer prevention, while noting both the benefits and the “potential risks” including the possibility of high-grade cancer, though a majority of the guideline panel judged that risk to be unlikely.¹⁵ That cautious framing reflects the state of evidence at the time; the long-term survival data and population-level registry studies published since then have made the case for finasteride’s safety considerably stronger.

The Cost of Chemoprevention

Even when a drug genuinely prevents cancer, whether it makes sense as a population-wide strategy depends on cost. A decision-analysis model estimated that finasteride-based chemoprevention would yield about 8.7 extra life-years per 1,000 men treated, but at a cost of over $1.1 million per life-year saved when the apparent high-grade risk was factored in. If finasteride was assumed not to increase high-grade tumors (consistent with the bias-adjusted analyses), the gain roughly doubled to 16.9 life-years per 1,000 men, and the cost per life-year saved dropped to about $578,000. To reach the commonly used threshold of $100,000 per life-year saved, finasteride would need to cost around $160 per year.¹⁶ Generic finasteride now costs well under that figure in many markets, which changes the math considerably from when the model was first published. Whether health systems will revisit finasteride as a formal chemoprevention strategy at current generic prices remains an open question, but the economic barrier looks much lower than it did a decade ago.

1
PubMed. The influence of finasteride on the development of prostate cancer
2
National Cancer Institute. Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard Parnes
3
PubMed. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial
4
PubMed Central. Finasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Bias-adjusted Modeling Approach
5
PubMed. Does finasteride alter the pathology of the prostate and cancer grading?
6
PubMed Central. Long-term survival of participants in the prostate cancer prevention trial
7
JAMA Oncology. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
8
British Journal of Cancer. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
9
PubMed. Effect of Dutasteride on the Risk of Prostate Cancer
10
PubMed. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial
11
PubMed. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations
12
The Lancet Oncology. Effect of finasteride 1 mg versus placebo over 48 weeks on serum PSA in men aged 40–60 years with androgenetic alopecia
13
PubMed. Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis
14
PubMed Central. Protocol for a randomised phase 3 trial evaluating the role of Finasteride in Active Surveillance for men with low and intermediate-risk prostate cancer: the FINESSE Study
15
PubMed Central. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
16
Cancer Epidemiology, Biomarkers & Prevention. The cost of prostate cancer chemoprevention: a decision analysis model